Breast cancer is the most frequently occurring cancer in women, which accounts for about one-third of cancer cases in women and more than 10% of all cancers worldwide.
Global Breast Cancer Antibodies Biomarkers & Clinical Trials Insight 2028 Report Highlights:
- Global Breast Cancer Antibodies Market Opportunity: > USD 15 Billion
- Breast Cancer Antibodies Clinical Trials Insight: > 150 Drugs In Trials
- Breast Cancer Biomarkers Sourced During Clinical Trials
- Breast Cancer Biomarkers Insight By Antibodies Classification
- Insight On Biomarkers Sourced From Trials By Drugs & Indication
- Biomarker Name & Function Insight By Antibody
- Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
Download Report: https://www.kuickresearch.com/ccformF.php?t=1646994975
Breast cancer is the most frequently occurring cancer in women, which accounts for about one-third of cancer cases in women and more than 10% of all cancers worldwide. Despite significant advances in the breast cancer treatment over last two decades, there is considerable rise in the breast cancer cases worldwide. The significant rise in the prevalence of breast cancer and the increasing mortality rates from them possess unmet need for the development of successful strategies for early detection and screening of the disease. For breast cancer, biomarkers are useful in identification of individuals which are at increased risk of developing the cancer within high-risk families, determining prognosis at the time of initial diagnosis, identifying the most appropriate systemic therapy, postoperative survillience, and monitoring therapy in advanced disease.
To date, numerous tissue biomarkers are used in breast cancer management, notably tissue expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Apart from this, serum biomarkers have also been identified which offer attractive alternative to tissue biomarkers, especially in the setting of monitoring for disease recurrence or progression, following response to treatment, and even determining targetable mutations to direct therapy. CA15-3, CA27-29, and CEA have shown to be useful adjuncts in the management of metastatic disease, particularly in monitoring response to treatment with serial measurement.
Among all targeted therapies, antiboidy therapeutics have the maximum share in the global breast cancer market. The rising adoption of novel antibody based therapies among the breast cancer patients have encouraged the pharmaceutical companies to identify novel biomarkers which can predict the outcome of antibody therapies in breast cancer patients. Established industry participants such as Roche Diagnostics, AstraZeneca, Novartis, Pfizer, Eli Lilly, Eisai, Celgene, Sanofi, MAQUET, Drager, and Breas Medical are concentrating on expanding their market presence by developing novel therapeutics that offer enhanced results. Companies are looking to form strategic alliances with regional players to extend their geographical reach. For instance in 2021, Freenome nnounced a partnership with Siemens Healthineers to collaborate in multiomics and radiomic breast cancer diagnostics to identify suitable markers for early breast cancer detection through blood to augment existing imaging technologies. The partnership leverages Freenome’s expertise in machine learning and multiomics to detect early cancer, utilizing epigenetic, proteomic, genomic, immunologic and other data types to maximize clinical accuracy for future screening tests.
As per our report findings, the global breast cancer antibodies market will surpass US$ 15 Billion by 2028. The increasing prevalence of breast cancer is a key factor propelling the growth of the market during the forecast period. Furthermore, the market is also witnessing a significant rise on account of the growing demand for drug discovery and development for various subtypes of breast cancer. In addition to this, several pharmaceutical giants are investing massive amounts into research and development of novel biomarkers for breast cancer therapeutics. Moreover, many clinical trials and pipeline studies are currently heading towards the end stages of development, and their market entry is likely to attract high cancer biomarkers market revenue during the forecast period. Apart from this, rising government initiatives to increase awareness regarding breast cancer will also have a positive impact on the growth of market.
This report on global breast cancer biomarkers market report provides holistic understanding of the market along with market sizing, forecast, drivers, challenges, and competitive landscape. Our report provides comprehensive analysis on the approved biomarkers for breast cancer immune checkpoint inhibitors. Apart from this, in-depth analysis on the ongoing clinical trials in biomarkers associated with immune checkpoint inhibitor therapy by various phases and therapeutic indications is also mentioned in the report. The major companies mentioned in the report are Amgen, Roche, Pfizer, Gilead Sciences, GlaxoSmthKline, and others.
Contact:
Neeraj Chawla
Research Head
Kuick Research
+91-9810410366